Last reviewed · How we verify
Intravenous administration of Methylprednisolone
Methylprednisolone is a corticosteroid that suppresses the immune system and reduces inflammation by inhibiting inflammatory mediators and immune cell activation.
Methylprednisolone is a corticosteroid that suppresses the immune system and reduces inflammation by inhibiting inflammatory mediators and immune cell activation. Used for Acute inflammatory and autoimmune conditions requiring rapid immunosuppression, Multiple sclerosis relapse, Severe allergic reactions.
At a glance
| Generic name | Intravenous administration of Methylprednisolone |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Methylprednisolone binds to glucocorticoid receptors in the cytoplasm, translocates to the nucleus, and modulates gene transcription to decrease production of pro-inflammatory cytokines, chemokines, and adhesion molecules. This results in reduced immune cell infiltration, decreased vascular permeability, and suppression of both innate and adaptive immune responses. Intravenous administration provides rapid systemic delivery for acute inflammatory or immunological conditions.
Approved indications
- Acute inflammatory and autoimmune conditions requiring rapid immunosuppression
- Multiple sclerosis relapse
- Severe allergic reactions
- Organ transplant rejection prophylaxis
Common side effects
- Hyperglycemia
- Insomnia
- Mood changes (euphoria, irritability)
- Hypertension
- Immunosuppression / increased infection risk
- Hypokalemia
- Gastrointestinal upset
Key clinical trials
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) (PHASE3)
- A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) (PHASE3)
- A Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Patients With Glycogen Storage Disease Type Ia (GSDIa) (PHASE3)
- A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011) (PHASE2)
- Effectiveness and Safety of Upadacitinib for Acute Severe Ulcerative Colitis
- A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (PHASE3)
- Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis (PHASE3)
- A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: